ZGNX Zogenix Inc.

41.44
-0.43  -1%
Previous Close 41.87
Open 41.69
Price To Book 3.23
Market Cap 1739154707
Shares 41,968,019
Volume 571,696
Short Ratio
Av. Daily Volume 577,343

NewsSee all news

  1. Edited Transcript of ZGNX earnings conference call or presentation 8-Nov-18 9:30pm GMT
  2. Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)
  3. Final trades: Home Depot, Target, Charter Communications,...
  4. What Kind Of Share Price Volatility Should You Expect For Zogenix Inc (NASDAQ:ZGNX)?
  5. Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170534
  3. 8-K - Current report 181169644
  4. 8-K - Current report 181110630
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181062825

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced November 29, 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 data released July 12, 2018. Primary endpoint met.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data released September 29, 2017 - primary endpoint met. Additional data rleased at American Epilepsy Society Annual Meeting December 3, 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Edited Transcript of ZGNX earnings conference call or presentation 8-Nov-18 9:30pm GMT
  2. Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)
  3. Final trades: Home Depot, Target, Charter Communications,...
  4. What Kind Of Share Price Volatility Should You Expect For Zogenix Inc (NASDAQ:ZGNX)?
  5. Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  6. Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
  7. Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
  8. Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
  9. Zogenix to Participate in the Global Mizuho Investor Conference 2018
  10. Zogenix: 3Q Earnings Snapshot
  11. Zogenix Provides Corporate Update and Reports Third Quarter Financial Results
  12. Zogenix to Present at Stifel 2018 Healthcare Conference
  13. The First Cannabis-Derived Drug Is Now on Pharmacy Shelves
  14. Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
  15. Zogenix Inc (NASDAQ:ZGNX): Is Breakeven Near?
  16. Zogenix Sees Hammer Chart Pattern: Time to Buy?
  17. Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

SEC Filings

  1. 8-K - Current report 181214017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170534
  3. 8-K - Current report 181169644
  4. 8-K - Current report 181110630
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181062825
  6. 8-K - Current report 181002309
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181002097
  8. 424B5 - Prospectus [Rule 424(b)(5)] 18995647
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18995454
  10. 8-K - Current report 18995094